Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nautilus Biotechnology, Inc.NAUT · Entity 6679 | Director · CEO, President, and Secretary · 10% owner | March 04, 2026 | March 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nautilus Biotechnology, Inc.
Report date March 04, 2026 · Filed March 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,366,721 |
Reported balance
After 2026-03-04 transaction · row 1
1 source rowRow 1 · 2026-03-04 · Purchase · Acquired 25,000 · Balance 10,366,721 F1: Represents the weighted average share price of an aggregate total of 25,000 shares purchased in the price range of $2.48 to $2.6095 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. |
| Common StockSEC Table I · non-derivative | IndirectBy PFV I, LLC | 5,280,476 |
Reported balance
Holding disclosure · report date 2026-03-04 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 5,280,476 F2: Shares held by PFV I, LLC. The reporting person is the manager of PFV I, LLC. |
| Common StockSEC Table I · non-derivative | IndirectBy Sujal Patel 2020 Children's Trust, u/a/d December 3, 2020 | 1,814,035 |
Reported balance
Holding disclosure · report date 2026-03-04 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,814,035 F3: Shares held by Sujal Patel 2020 Children's Trust, u/a/d December 3, 2020 (the "Patel Trust"). The reporting person and the reporting person's spouse are the trustees of the Patel Trust. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the weighted average share price of an aggregate total of 25,000 shares purchased in the price range of $2.48 to $2.6095 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
F2: Shares held by PFV I, LLC. The reporting person is the manager of PFV I, LLC.
F3: Shares held by Sujal Patel 2020 Children's Trust, u/a/d December 3, 2020 (the "Patel Trust"). The reporting person and the reporting person's spouse are the trustees of the Patel Trust.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 04, 2026 Filed Mar 4, 2026 23:37 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | PurchaseCommon Stock | 25,000 | $2.61 | $65,237.50 |
DisclosureSEC source: 0001378830-26-000003 · wk-form4_1772667437.xml · nonDerivative · entry 1 Patel Sujal M · CIK 0001378830 · Director · CEO, President, and Secretary · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,366,721 F1 · price: Represents the weighted average share price of an aggregate total of 25,000 shares purchased in the price range of $2.48 to $2.6095 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 22:31 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | GrantStock Option (Right to Buy) · Derivative | 650,000 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001378830-26-000001 · wk-form4_1772663485.xml · derivative · entry 1 Patel Sujal M · CIK 0001378830 · Director · CEO, President, and Secretary · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 650,000 Underlying: Common Stock · 650,000 shares Expires 2036-03-02 F1 · derivative.exercise_date: Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2026. Read SEC document |
| September 08, 2025 Filed Sep 9, 2025 20:42 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | PurchaseCommon Stock | 83,500 | $0.68 | $57,030.50 |
DisclosureSEC source: 0001378830-25-000003 · wk-form4_1757450542.xml · nonDerivative · entry 2 Patel Sujal M · CIK 0001378830 · Director · CEO, President, and Secretary · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,341,721 F2 · price: Represents the weighted average share price of an aggregate total of 83,500 shares purchased in the price range of $0.6581 to $0.7145 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| September 05, 2025 Filed Sep 9, 2025 20:42 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | PurchaseCommon Stock | 116,500 | $0.67 | $78,544.30 |
DisclosureSEC source: 0001378830-25-000003 · wk-form4_1757450542.xml · nonDerivative · entry 1 Patel Sujal M · CIK 0001378830 · Director · CEO, President, and Secretary · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,258,221 F1 · price: Represents the weighted average share price of an aggregate total of 116,500 shares purchased in the price range of $0.6547 to $0.6899 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| March 20, 2025 Filed Mar 21, 2025 20:44 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | PurchaseCommon Stock | 23,933 | $1.00 | $23,889.92 |
DisclosureSEC source: 0001808805-25-000034 · wk-form4_1742589871.xml · nonDerivative · entry 2 Patel Sujal M · CIK 0001378830 · Director · CEO, President, and Secretary · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,141,721 F2 · price: Represents the weighted average share price of an aggregate total of 23,933 shares purchased in the price range of $0.9351 to $1.06 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| March 19, 2025 Filed Mar 21, 2025 20:44 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | PurchaseCommon Stock | 53,300 | $0.99 | $53,028.17 |
DisclosureSEC source: 0001808805-25-000034 · wk-form4_1742589871.xml · nonDerivative · entry 1 Patel Sujal M · CIK 0001378830 · Director · CEO, President, and Secretary · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,117,788 F1 · price: Represents the weighted average share price of an aggregate total of 53,300 shares purchased in the price range of $0.9469 to $1.10 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 21:51 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | GrantStock Option (Right to Buy) · Derivative | 650,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001808805-25-000020 · wk-form4_1741125091.xml · derivative · entry 1 Patel Sujal M · CIK 0001378830 · Director · CEO, President, and Secretary · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 650,000 Underlying: Common Stock · 650,000 shares Expires 2035-03-03 F1 · derivative.exercise_date: 25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the Vesting Commencement Date, as defined below, and the balance of the shares subject to the Option shall vest and become exercisable on a ratable, monthly basis over the 36 months succeeding such first anniversary so long as the Reporting Person remains a Service Provider as provided in the Issuer's 2021 Equity Incentive Plan. Vesting Commencement Date shall mean January 1, 2025. Read SEC document |
| March 11, 2024 Filed Mar 12, 2024 00:21 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | PurchaseCommon Stock | 12,044 | $2.84 | $34,215.80 |
DisclosureSEC source: 0001808805-24-000026 · wk-form4_1710202909.xml · nonDerivative · entry 2 Patel Sujal M · CIK 0001378830 · Director · CEO, President, and Secretary · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,064,488 F2 · price: Represents the weighted average share price of an aggregate total of 12,044 shares purchased in the price range of $2.75 to $3.00 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| March 08, 2024 Filed Mar 12, 2024 00:21 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | PurchaseCommon Stock | 2,430 | $2.99 | $7,262.06 |
DisclosureSEC source: 0001808805-24-000026 · wk-form4_1710202909.xml · nonDerivative · entry 1 Patel Sujal M · CIK 0001378830 · Director · CEO, President, and Secretary · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,052,444 F1 · price: Represents the weighted average share price of an aggregate total of 2,430 shares purchased in the price range of $2.96 to $3.00 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| March 07, 2024 Filed Mar 8, 2024 00:06 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | PurchaseCommon Stock | 18,854 | $2.89 | $54,423.96 |
DisclosureSEC source: 0001628280-24-009754 · wk-form4_1709856399.xml · nonDerivative · entry 3 Patel Sujal M · CIK 0001378830 · Director · CEO, President, and Secretary · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,050,014 F3 · price: Represents the weighted average share price of an aggregate total of 18,854 shares purchased in the price range of $2.72 to $3.00 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 00:06 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | PurchaseCommon Stock | 9,267 | $2.70 | $25,033.87 |
DisclosureSEC source: 0001628280-24-009754 · wk-form4_1709856399.xml · nonDerivative · entry 2 Patel Sujal M · CIK 0001378830 · Director · CEO, President, and Secretary · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,031,160 F2 · price: Represents the weighted average share price of an aggregate total of 9,267 shares purchased in the price range of $2.64 to $2.77 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| March 05, 2024 Filed Mar 8, 2024 00:06 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | PurchaseCommon Stock | 7,405 | $2.65 | $19,596.59 |
DisclosureSEC source: 0001628280-24-009754 · wk-form4_1709856399.xml · nonDerivative · entry 1 Patel Sujal M · CIK 0001378830 · Director · CEO, President, and Secretary · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,021,893 F1 · price: Represents the weighted average share price of an aggregate total of 7,405 shares purchased in the price range of $2.58 to $2.69 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:52 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | GrantStock Option (Right to Buy) · Derivative | 650,000 | $0.00 Strike: $2.72 | $0.00 |
DisclosureSEC source: 0001808805-24-000024 · wk-form4_1709675514.xml · derivative · entry 1 Patel Sujal M · CIK 0001378830 · Director · CEO, President, and Secretary · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 650,000 Underlying: Common Stock · 650,000 shares Expires 2034-03-01 F1 · derivative.exercise_date: Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2024. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 22:20 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | GrantStock Option (Right to Buy) · Derivative | 650,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001808805-23-000032 · wf-form4_167770917669467.xml · derivative · entry 1 Patel Sujal M · CIK 0001378830 · Director · CEO, President, and Secretary · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 650,000 Underlying: Common Stock · 650,000 shares Expires 2033-02-27 F1 · derivative.exercise_date: Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2023. Read SEC document |
| August 08, 2022 Filed Aug 8, 2022 23:48 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | PurchaseCommon Stock | 8,346 | $2.93 | $24,443.76 |
DisclosureSEC source: 0001808805-22-000089 · wf-form4_166000250690193.xml · nonDerivative · entry 2 Patel Sujal M · CIK 0001378830 · Director · CEO, President, and Secretary · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,014,488 F2 · price: Represents the weighted average share price of an aggregate total of 8,346 shares purchased in the price range of $2.90 to $3.00 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 05, 2022 Filed Aug 8, 2022 23:48 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | PurchaseCommon Stock | 41,654 | $2.92 | $121,646.34 |
DisclosureSEC source: 0001808805-22-000089 · wf-form4_166000250690193.xml · nonDerivative · entry 1 Patel Sujal M · CIK 0001378830 · Director · CEO, President, and Secretary · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,006,142 F1 · price: Represents the weighted average share price of an aggregate total of 41,654 shares purchased in the price range of $2.76 to $3.00 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 09, 2022 Filed May 11, 2022 00:28 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | PurchaseCommon Stock | 50,000 | $3.96 | $198,000.00 |
DisclosureSEC source: 0001808805-22-000054 · wf-form4_165222886775160.xml · nonDerivative · entry 1 Patel Sujal M · CIK 0001378830 · Director · CEO, President, and Secretary · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,964,488 F1 · price: Represents the weighted average share price of an aggregate total of 50,000 shares purchased in the price range of $3.8299 to $4.00 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| March 04, 2022 Filed Mar 4, 2022 22:39 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | Exercise / conversionCommon Stock | 100 | $10.00 | $1,000.00 |
DisclosureSEC source: 0001808805-22-000026 · wf-form4_164643353372172.xml · nonDerivative · entry 2 Patel Sujal M · CIK 0001378830 · Director · CEO, President, and Secretary · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,914,488 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2022 Filed Mar 4, 2022 22:39 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | Exercise / conversionStock Option (Right to Buy) · Derivative | 100 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001808805-22-000026 · wf-form4_164643353372172.xml · derivative · entry 5 Patel Sujal M · CIK 0001378830 · Director · CEO, President, and Secretary · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 788,733 Underlying: Common Stock · 100 shares Expires 2031-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Subject to reporting person's continuous status as a "Service Provider" (as defined in the Nautilus Subsidiary, Inc. 2017 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement date is January 31, 2021. Read SEC document |
| March 03, 2022 Filed Mar 4, 2022 22:39 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | PurchaseCommon Stock | 50,000 | $3.60 | $179,890.00 |
DisclosureSEC source: 0001808805-22-000026 · wf-form4_164643353372172.xml · nonDerivative · entry 1 Patel Sujal M · CIK 0001378830 · Director · CEO, President, and Secretary · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,914,388 F1 · price: Represents the weighted average share price of an aggregate total of 50,000 shares purchased in the price range of $3.57 to $3.60 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 25, 2022 Filed Feb 26, 2022 01:09 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | GrantStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0001808805-22-000023 · wf-form4_164583775921533.xml · derivative · entry 1 Patel Sujal M · CIK 0001378830 · Director · CEO, President, and Secretary · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2032-02-25 F1 · derivative.exercise_date: Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is February 25, 2022. Read SEC document |
| December 01, 2021 Filed Dec 2, 2021 13:49 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | PurchaseCommon Stock | 88,022 | $4.73 | $416,396.87 |
DisclosureSEC source: 0001808805-21-000027 · wf-form4_163845298373636.xml · nonDerivative · entry 2 Patel Sujal M · CIK 0001378830 · Director · CEO, President, and Secretary · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,864,388 F2 · price: Represents the weighted average share price of an aggregate total of 88,022 shares purchased in the price range of $4.44 to $5.00 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 13:49 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | PurchaseCommon Stock | 161,978 | $4.72 | $764,779.13 |
DisclosureSEC source: 0001808805-21-000027 · wf-form4_163845298373636.xml · nonDerivative · entry 1 Patel Sujal M · CIK 0001378830 · Director · CEO, President, and Secretary · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,776,366 F1 · price: Represents the weighted average share price of an aggregate total of 161,978 shares purchased in the price range of $4.48 to $4.85 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.